Gravidomimetic Prevention of Breast Cancer
Abstract
To test the hypothesis that a novel synthetic peptide can prevent breast cancer, we utilized a standard model to induce breast cancer in rats and initiated a dose-finding study in which four log doses of peptide were administered daily beginning 10 days after treatment with carcinogen, and lasting for 23 days, a time period that mimics pregnancy. Treatment with peptide was then discontinued, and animals were palpated for tumors daily for 100 days. The number of animals with tumors, number of tumors per animal, time to generation of palpable tumors, and mass of tumors (at autopsy) were noted as endpoints, and weight, weight gain, cage activity and fur texture were used as gross assessments of toxicity. The study was not complete at the time of report preparation, but to date no evidence of toxicity due to the peptide has been noted. Early generation of tumors associated with pregnancy was not observed, suggesting that the anti-oncotic peptide does not posses an undesirable immunosuppressive activity. Pre-1OO day data indicate fewer cancers in the Peptide- compared to No Peptide groups. We conclude that the model can appropriately assess prevention capability and should generate data concerning dosages for use in assessing the gravidomimetic prevention potential of this novel drug.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2002
- Accession Number
- ADA406139
Entities
People
- Thomas T. Andersen
Organizations
- Albany Medical College